Hill N C, Selinger M, Ferguson J, MacKenzie I Z
Nuffield Department of Obstetrics and Gynaecology, University of Oxford, John Radcliffe Hospital, Headington.
Br J Obstet Gynaecol. 1990 May;97(5):406-11. doi: 10.1111/j.1471-0528.1990.tb01827.x.
A double-blind, placebo-controlled study has assessed the maternal and fetal endocrine effects of the maternal administration of the anti-progestin mifepristone in mid-pregnancy. There were six women in each group. Four hours after oral administration of 600 mg mifepristone, the drug was detected in both maternal and fetal circulations and in the amniotic fluid. No significant changes in progesterone, cortisol, oestradiol, or aldosterone concentrations were detected in the maternal circulation after treatment with mifepristone or placebo. In women treated with mifepristone, the mean fetal aldosterone level was 1699 (SD 217) pmol/l which was significantly higher than the mean level of 999 (SD 84) pmol/l in the control group but no significant changes occurred in the fetal progesterone, oestradiol or cortisol concentrations. The significance of these results is discussed in relation to the possible therapeutic uses of mifepristone for inducing labour.
一项双盲、安慰剂对照研究评估了孕中期母体服用抗孕激素米非司酮对母体和胎儿内分泌的影响。每组有6名女性。口服600毫克米非司酮4小时后，在母体和胎儿循环以及羊水中均检测到该药物。米非司酮或安慰剂治疗后，母体循环中孕酮、皮质醇、雌二醇或醛固酮浓度未检测到显著变化。在接受米非司酮治疗的女性中，胎儿醛固酮平均水平为1699（标准差217）pmol/l，显著高于对照组的平均水平999（标准差84）pmol/l，但胎儿孕酮、雌二醇或皮质醇浓度未发生显著变化。结合米非司酮诱导分娩的可能治疗用途对这些结果的意义进行了讨论。
